Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Nov 08 04:00PM ET
0.3273
Dollar change
+0.0051
Percentage change
1.58
%
Index- P/E- EPS (ttm)-1.31 Insider Own25.69% Shs Outstand33.56M Perf Week-10.33%
Market Cap11.15M Forward P/E- EPS next Y-0.67 Insider Trans0.00% Shs Float24.94M Perf Month-15.51%
Income-28.90M PEG- EPS next Q-0.22 Inst Own31.84% Short Float3.36% Perf Quarter-40.33%
Sales0.00M P/S- EPS this Y57.67% Inst Trans-22.68% Short Ratio1.64 Perf Half Y-59.21%
Book/sh0.52 P/B0.63 EPS next Y16.25% ROA-101.76% Short Interest0.84M Perf Year-62.38%
Cash/sh0.48 P/C0.68 EPS next 5Y- ROE-146.03% 52W Range0.32 - 9.37 Perf YTD-72.26%
Dividend Est.- P/FCF- EPS past 5Y-283.70% ROI-179.02% 52W High-96.51% Beta1.23
Dividend TTM- Quick Ratio3.43 Sales past 5Y0.00% Gross Margin- 52W Low2.92% ATR (14)0.04
Dividend Ex-Date- Current Ratio3.43 EPS Y/Y TTM50.35% Oper. Margin0.00% RSI (14)28.63 Volatility10.13% 8.19%
Employees42 Debt/Eq0.12 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price6.00
Option/ShortNo / Yes LT Debt/Eq0.05 EPS Q/Q91.00% Payout- Rel Volume0.57 Prev Close0.32
Sales Surprise- EPS Surprise75.61% Sales Q/Q- EarningsAug 08 AMC Avg Volume511.96K Price0.33
SMA20-10.61% SMA50-40.74% SMA200-78.68% Trades Volume290,701 Change1.58%
Date Action Analyst Rating Change Price Target Change
Jan-14-22Initiated H.C. Wainwright Buy $25
Dec-23-21Initiated Cantor Fitzgerald Overweight $25
Nov-01-21Initiated SVB Leerink Outperform $24
Sep-13-21Initiated Laidlaw Buy $30
Aug-25-21Initiated B. Riley Securities Buy $26
Oct-10-24 12:00PM
Oct-07-24 04:05PM
Aug-08-24 04:30PM
Jun-29-24 08:50PM
08:48PM
08:45PM Loading…
08:45PM
08:43PM
08:40PM
08:37PM
08:35PM
08:32PM
08:28PM
08:26PM
06:30PM
Jun-27-24 12:00PM
09:54PM Loading…
May-14-24 09:54PM
04:15PM
Apr-26-24 06:35AM
12:27AM
Apr-25-24 04:01PM
Apr-09-24 01:34PM
12:29PM
08:40AM
Apr-08-24 04:30PM
Apr-02-24 07:53AM
Apr-01-24 08:00AM
Mar-29-24 04:51PM
03:20PM
Mar-14-24 09:38AM
Mar-05-24 04:31PM
03:00PM Loading…
Jan-07-24 03:00PM
Dec-10-23 12:00PM
Nov-14-23 07:00AM
Nov-02-23 09:10AM
Oct-13-23 09:12AM
Oct-06-23 09:30AM
Sep-19-23 07:00AM
Sep-14-23 07:00AM
Aug-22-23 07:30AM
Aug-07-23 09:25AM
May-11-23 04:05PM
Apr-19-23 09:05AM
Apr-17-23 01:35PM
08:00AM
Mar-28-23 04:05PM
Mar-14-23 04:35PM
Feb-06-23 08:00AM
Dec-13-22 09:29AM
Dec-12-22 04:05PM
Dec-11-22 10:05AM
Nov-10-22 04:05PM
Nov-03-22 09:05AM
Aug-11-22 04:05PM
09:43AM
Jul-01-22 06:03AM
Jun-10-22 08:00AM
Jun-07-22 02:11PM
08:25AM
Jun-06-22 04:05PM
06:24AM
May-12-22 04:05PM
Apr-08-22 01:05PM
Mar-29-22 08:00AM
Mar-08-22 04:35PM
Feb-09-22 08:00AM
Feb-03-22 08:30AM
Jan-30-22 06:32PM
Dec-28-21 09:35AM
Dec-17-21 08:00AM
Dec-11-21 03:30PM
Dec-07-21 08:00AM
Dec-06-21 08:00AM
Nov-12-21 08:00AM
Nov-04-21 09:01AM
Sep-16-21 07:30AM
Sep-07-21 08:00AM
Aug-12-21 04:05PM
Jul-30-21 09:55AM
Jul-01-21 02:42AM
Jun-28-21 08:00AM
Jun-04-21 12:40PM
08:00AM
Jun-03-21 04:05PM
May-26-21 08:00AM
May-17-21 08:00AM
May-06-21 08:00AM
Apr-20-21 08:00AM
Apr-10-21 08:31AM
Apr-07-21 08:00AM
Apr-05-21 08:00AM
Apr-01-21 08:00AM
Mar-30-21 09:24AM
Mar-23-21 08:00AM
Mar-10-21 04:32PM
Mar-02-21 08:00AM
Feb-24-21 08:00AM
Feb-17-21 08:00AM
Jan-07-21 04:01PM
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. It focuses on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The firm pipeline is derived from a license agreement with Bayer and includes: a clinical-stage and follow-on small molecule drug program and preclinical stage bioconjugation/next-generation antibody-drug conjugate platform. The company was founded by Ahmed M. Hamdy, Raquel E. Izumi, Tom C. Thomas, Soo In Hwang and John C. Byrd on December 19, 2018 and is headquartered in Palo Alto, CA.